drugset / Trial / NCT03624543

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

NCT03624543

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of the disease and relieve some symptoms of cancer. Patients will have already had at least one chemotherapy treatment for their disease at this stage.

Timeline

Start
2019-02-14
Primary completion
2026-06-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject OCIFISERTIB Small molecule 32 mg

Indications